Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Prism Conformity Trial for Post-Traumatic Stress Disorder in Adolescents
Sponsor: GrayMatters Health Ltd.
Summary
Prism is a software as a medical device (SaMD) to be prescribed by clinicians as an adjunct to the standard of care treatment of patients with PTSD. The Prism software device runs on a laptop using an EEG signal input (g).Nautilos PRO (K171669). The primary objective of the study is to extend the use of the FDA cleared Prism for PTSD (K222101) to an adolescent population and to confirm the safety of fifteen (15±3) EEG-NF training sessions using the Prism software in reducing PTSD-related symptoms in adolescents. The study aims to demonstrate the safety profile of Prism, having no device-related serious adverse events (SAEs), consistent with findings in the adult population, throughout the course of Prism treatment in an adolescent population.
Official title: A Prospective, Single Arm, Open Label Trial, to Confirm Safety and Effectiveness of Prism, as an Adjunct to Standard of Care, in Adolescents With Post-Traumatic Stress Disorder (PTSD)
Key Details
Gender
All
Age Range
12 Years - 21 Years
Study Type
INTERVENTIONAL
Enrollment
45
Start Date
2025-06-11
Completion Date
2026-11-01
Last Updated
2025-12-10
Healthy Volunteers
No
Interventions
Prism
Prism is using an amygdala-fMRI-guided model for processing EEG signals. The model, termed EEG fMRI pattern (EFP), uses several electrodes EEG-signal to produce a real time amygdala-EFP biomarker signal. GrayMatters' product, Prism, is used to train patients in downregulating the amygdala-derived-EFP biomarker during therapy sessions.
Locations (1)
NYU Langone Health
New York, New York, United States